Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Plasma and tumor cells from 103 patients with leukemia or lymphoma at initial presentation were investigated for the presence of plasminogen activator inhibitor-2 (PAI-2) antigen, a potent inhibitor of urokinase. PAI-2 was detected in plasma and leukemic cells of the 21 patients with leukemia having a monocytic component [acute myelomonocytic (M4), acute monoblastic (M5), and chronic myelomonocytic leukemias], and in the three patients with acute undifferentiated myeloblastic leukemia (M0). In contrast, this serine protease inhibitor was undetectable in 79 patients with other subtypes of acute myeloid leukemia or other hematological malignancies. Serial serum PAI-2 determinations in 16 patients with acute leukemia at presentation, during therapy, remission, and relapse revealed that in the five patients with M4-M5, elevated PAI-2 levels rapidly normalized under therapy and during remission, but increased again in the patients with a relapse associated with an M4-M5 phenotype. Thus, PAI-2 seems to be a marker highly specific for the active stages of monocytic leukemia, i.e. presentation and relapse. The presence of PAI-2 in the plasma and cells of patients with M0 may give a clue to a monocytic origin of these cells.
Scherrer
A
A
Department of Medicine, University Hospital Center, Lausanne, Switzerland.
Kruithof
E K
EK
Grob
J P
JP
D000951:Antigens, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007948:Leukemia, Monocytic, Acute / Q000175:diagnosis* / Q000276:immunology; D015479:Leukemia, Myelomonocytic, Acute / Q000175:diagnosis / Q000276:immunology; D015477:Leukemia, Myelomonocytic, Chronic / Q000175:diagnosis / Q000276:immunology; D015849:Plasminogen Inactivators / Q000097:blood / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000378:metabolism
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015849:Plasminogen Inactivators